Many of the rarest and most difficult-to-treat diseases are caused by a single gene mutation, making routine pharmaceutical and surgical treatments ineffective. On the other hand, cell and gene therapies have emerged as more effective possibilities, allowing diseases to be attacked at the cellular level.
However, while cell and gene therapies provide a more personalized approach to treating uncommon disorders, they can be costly and complicated. Scientists connect a modified or healthy version of a molecule to a viral vector, a microscopic mechanism that carries the molecule into the targeted cell, in the most typical way.
Ex vivo delivery of cell and gene therapies into any cell, no matter how fragile, is possible with Mekonos‘ “system-on-a-chip” platform, which employs arrays of hundreds of silicon nanoneedles. In addition, Mekonos‘ chip technology, powered by miniature electro-mechanical systems, microfluidics, and chemistry, is reusable and can deliver many therapeutic payloads at once, making it a promising therapy option for several ailments.